FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Related Topics >> Provenge | Dendreon

NEJM lays out questions--and facts--about Provenge

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

Shares of Dendreon (NASDAQ: DNDN) soared into the stratosphere in the lead-up to Provenge's approval--and then promptly started tumbling fast as all sorts of questions arose about supply issues and efficacy. The company is likely to benefit enormously from the publication of its biggest study of the innovative prostate cancer vaccine in the prestigious New England Journal of Medicine, which carries biblical weight with providers.

The facts about the Provenge data have been known for some time; the drug demonstrated a 22.5 percent reduction in the risk of death and a 4.1 month increase in median survival rates compared with a placebo. Earlier stage patients benefited with significantly longer survival rates. Forbes' Matthew Herper notes that it's significant that the survival data is consistent, and he offers kudos for getting Dana Farber's well-respected Philip Kantoff as the lead author.

"These results represent the beginning of a new era in the treatment of cancer, one in which a patient's own immune system is harnessed to fight the disease," says Kantoff in a statement. "Furthermore, the magnitude of the survival benefit coupled with the side effect profile and short duration of therapy place Provenge as a new standard of care for men with asymptomatic or minimally symptomatic mCRPC."

But there was also some skepticism about the new drug. In particular, Herper notes, the study raises questions about the drug's benefit, including the absence of a "measurable effect on tumors." Dan Longo, a deputy editor at the New England Journal of Medicine, calls that "hard to understand" in an accompanying editorial.

Provenge is also radically more expensive than current prostate cancer therapies. At $93,000, physicians and payers will have to question a drug that costs $23,000 a month versus the $1,800 monthly fee they currently face.

- check out the press release
- here's Herper's report in Forbes
- read the story from TheStreet

Related Articles:
Dendreon shares routed by Medicare Provenge review news
Provenge gets clean bill of health on safety, side effects
Hunt for the next big cancer vaccine fraught with peril


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Provenge   Dendreon  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.